Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction

2007 ◽  
Vol 25 (25) ◽  
pp. 3985-3990 ◽  
Author(s):  
Michael J. Callahan ◽  
Christopher P. Crum ◽  
Fabiola Medeiros ◽  
David W. Kindelberger ◽  
Julia A. Elvin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Fallopian Tube ◽  
Brca Mutation ◽  
Gynecologic Oncology ◽  
Prophylactic Surgery ◽  
Ovarian Cancer Risk ◽  
Brca Mutations ◽  
Cancer Risk Reduction

Purpose To review the frequency and location of malignancies detected after prophylactic salpingo-oophorectomy in women with BRCA mutations. Methods Medical records and pathology findings were reviewed from BRCA-positive women undergoing prophylactic surgery for ovarian cancer risk reduction who underwent complete examination of the adnexa. Patients undergoing this procedure between January 1999 and January 2007 were identified. Results From January 1999 to January 2007, 122 BRCA-positive patients underwent prophylactic surgery in the Division of Gynecologic Oncology at Brigham and Women's Hospital. The median age was 46.5 years (range, 33 to 76 years). Seven (5.7%) were found to have an early malignancy in the upper genital tract and all patients were age ≥ 44 years at diagnosis. Of seven consecutive cancers culled between January 1999 and January 2007, all (100%) originated in the fimbrial or ampullary region of the tube; six had an early (intraepithelial) component. Two were associated with surface implants on the ovary and two required repeated sectioning to detect microscopic carcinomas in the fimbria. Conclusion The distal fallopian tube seems to be the dominant site of origin for early malignancies detected in approximately 6% of women undergoing ovarian cancer risk-reduction surgery. The greatest proportion of serous cancer risk in BRCA mutation–positive women should be assigned to the fimbria rather than the ovary, and future clinical and research protocols should employ thorough examination of the fimbria, including multiple sections from each tissue block, to maximize detection of early malignancies in this population.

Completeness of salpingectomy intended for ovarian cancer risk reduction

2019 ◽  
Vol 155 (2) ◽  
pp. 280-282 ◽  
Author(s):  
Jennifer W.H. Wong ◽  
Jeffrey L. Killeen ◽  
Michael E. Carney
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Ovarian Cancer Risk ◽  
Cancer Risk Reduction

scholarly journals The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction

2019 ◽  
Vol 152 (1) ◽  
pp. 127-132 ◽  
Author(s):  
Akila Subramaniam ◽  
Brett D. Einerson ◽  
Christina T. Blanchard ◽  
Britt K. Erickson ◽  
Jeff Szychowski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cost Effectiveness ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Cesarean Delivery ◽  
Tubal Ligation ◽  
Ovarian Cancer Risk ◽  
The Cost ◽  
Opportunistic Salpingectomy ◽  
Cancer Risk Reduction

scholarly journals Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Michelle Jacobson ◽  
Nadia Coakley ◽  
Marcus Bernardini ◽  
Kelly-Ann Branco ◽  
Laurie Elit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Hormone Replacement ◽  
Breast Cancer Mortality ◽  
Pathogenic Variant ◽  
Ovarian Cancer Risk ◽  
Eligibility Criteria ◽  
Cancer Risk Reduction

Abstract Objective The purpose of this guideline is to make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2. Methods Draft recommendations were formulated based on evidence obtained through a systematic review of RCTs, comparative retrospective studies and guideline endorsement. The draft recommendations underwent an internal review by clinical and methodology experts, and an external review by clinical practitioners. Results The literature search yielded 1 guideline, 5 systematic reviews, and 15 studies that met the eligibility criteria. Conclusions In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 screening for ovarian cancer is not recommended. Risk-reducing surgery is recommended to reduce the risk of ovarian cancer. In the absence of contraindications, premenopausal women undergoing RRSO should be offered hormone therapy until menopause. Systemic hormone replacement therapy, is not recommended for women who have had a personal history of breast cancer. RRSO should be considered for breast cancer risk reduction in women younger than 50 years. After a breast cancer diagnosis, RRSO for breast cancer mortality reduction can be considered within two years to women who harbour a pathogenic or likely pathogenic variant in BRCA1 if younger than the recommended age range for ovarian cancer risk reduction. RRSO before the age of 40 and specifically for breast cancer treatment in BRCA2 should be considered only if recommended by their breast cancer oncologist. Following RRSO, it is not recommended to do surveillance for peritoneal cancer.

Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations

2018 ◽  
Vol 150 (1) ◽  
pp. 79-84 ◽  
Author(s):  
Denise R. Nebgen ◽  
Jean Hurteau ◽  
Laura L. Holman ◽  
Andrea Bradford ◽  
Mark F. Munsell ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Pilot Study ◽  
Cancer Risk ◽  
Risk Reduction ◽  
Ovarian Cancer Risk ◽  
Bilateral Salpingectomy ◽  
Cancer Risk Reduction

scholarly journals Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location

Genes ◽  
2021 ◽  
Vol 12 (7) ◽  
pp. 1050
Author(s):  
Masayuki Sekine ◽  
Koji Nishino ◽  
Takayuki Enomoto
Keyword(s):  
Ovarian Cancer ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Brca Mutation ◽  
Parp Inhibitors ◽  
Individual Risk ◽  
Ovarian Cancer Risk ◽  
Founder Mutations ◽  
Brca Mutations ◽  
Germline Brca Mutation

Hereditary breast and ovarian cancer is caused by a germline mutation in BRCA1 or BRCA2 genes. The frequency of germline BRCA1/2 gene mutation carriers and the ratio of germline BRCA1 to BRCA2 mutations in BRCA-related cancer patients vary depending on the population. Genotype and phenotype correlations have been reported in BRCA mutant families, however, the correlations are rarely used for individual risk assessment and management. BRCA genetic testing has become a companion diagnostic for PARP inhibitors, and the number of families with germline BRCA mutation identified is growing rapidly. Therefore, it is expected that analysis of the risk of developing cancer will be possible in a large number of BRCA mutant carriers, and there is a possibility that personal and precision medicine for the carriers with specific common founder mutations will be realized. In this review, we investigated the association of ovarian cancer risk and BRCA mutation location, and differences of other BRCA-related cancer risks by BRCA1/2 mutation, and furthermore, we discussed the difference in the prevalence of germline BRCA mutation in ovarian cancer patients. As a result, although there are various discussions, there appear to be differences in ovarian cancer risk by population and BRCA mutation location. If it becomes possible to estimate the risk of developing BRCA-related cancer for each BRCA mutation type, the age at risk-reducing salpingo-oophorectomy can be determined individually. The decision would bring great benefits to young women with germline BRCA mutations.

Sign in / Sign up

Export Citation Format

Share Document